Despite the capacity of this therapy to increase the risk of infections [9], patients undergoing treatment with TNF-α inhibitors exhibit a reduced susceptibility to adverse outcomes associated with COVID-19 in contrast to those receiving GCs. Here, TNF is linked to COVID-19.